[55] investigated the anti‐myostatin antibody LY2495655 in 125 patients with Stage II–IV pancreatic cancer given in two different doses (100 and 300 mg) compared to standard treatment alone without an effect on OS. Here, MSTN is linked to familial pancreatic carcinoma.